In what is the result of a collaborative project between Australia Department of Health and Aging, the Pharmaceutical Benefits Advisory Committee and the trade body Medicines Australia, the first ever report on Pharmaceutical Benefit Scheme activity indicators has been released. The primary purpose of this is to facilitate the identification of trends in the process of adding items to the PBS that may provide the basis for further dialog.
The initiative was welcomed by Medicines Australia, which said this provides greater transparency to PBS outcomes. It allows new insights into the decision-making of the PBAC, the body which assesses the cost effectiveness of new medicines before they are listed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze